In collection, these data reveal the benefits of MEG3 in alleviating NAFLD and suggest these benefits are associated with downregulating EZH2, upregulating SIRT6, and suppressing lipogenesis and inflammation. Here, SIRT6 is linked to metabolic dysfunction-associated steatotic liver disease.